Company profile
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the
- CEO
- Mr. James Bligh
- Headquarters
- Naples, FL, United States
- Employees
- 4
- IPO date
- Sep 25, 2023
- Sector
- Healthcare
- Industry
- Biotechnology